Jacobs Levy Equity Management, Inc Prelude Therapeutics Inc Transaction History
Jacobs Levy Equity Management, Inc
- $25.8 Billion
- Q4 2024
A detailed history of Jacobs Levy Equity Management, Inc transactions in Prelude Therapeutics Inc stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 666,574 shares of PRLD stock, worth $599,916. This represents 0.0% of its overall portfolio holdings.
Number of Shares
666,574
Previous 174,979
280.95%
Holding current value
$599,916
Previous $362,000
133.7%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding PRLD
# of Institutions
59Shares Held
30.4MCall Options Held
6.4KPut Options Held
0-
Orbimed Advisors LLC San Diego, CA10.9MShares$9.82 Million0.38% of portfolio
-
Baker Bros. Advisors LP New York, NY10.1MShares$9.11 Million0.14% of portfolio
-
Black Rock Inc. New York, NY1.07MShares$962,0240.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.03MShares$926,2790.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.01MShares$909,3520.0% of portfolio
About Prelude Therapeutics Inc
- Ticker PRLD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,369,200
- Market Cap $32.7M
- Description
- Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...